cms.bioaccessla.com

Category: Market Access Services in Latin America

Explores the regulatory requirements and best practices for obtaining marketing authorization, market clearance, and regulatory registrations in the top Latin American countries—Mexico’s Cofepris, Colombia’s Invima, Brazil’s Anvisa, and Argentina’s Anmat—market entry, and market access in Latin America, focusing on innovative medical devices.

  • REGULATE México COFEPRIS Holder vs bioaccess® LATAM Launch Subscription

    The URL regulate.com.mx/holder-mexico-cofepris is an exact-match page for “Mexico Registration Holder COFEPRIS.” REGULATE México is a homegrown shop that sells legal representation before COFEPRIS for foreign manufacturers that do not have a Mexican office. That is a legitimate one-country titular product. This page describes what REGULATE actually publishes, then contrasts it with the multi-country holder subscription from bioaccess®.

    What REGULATE México publishes

    The holder page (retrieved 23 August 2026) walks a three-step COFEPRIS path: (1) alta de establecimiento — aviso de funcionamiento and responsable sanitario for a Mexico-constituted company that will appear on the sanitary registration; (2) product notification / registro sanitario; (3) activity permits for import and publicity once the registro exists. For foreign firms it contrasts three models:

    • Filial in Mexico — the manufacturer’s own titular. Advantages: control of timelines. Disadvantages they list: investment, time to constitute, a declared physical domicile, a quality system, and a farmaco / tecnovigilancia unit.
    • Holder (“empresa estratégica”) — an establishment already notified to COFEPRIS, with a health professional as responsable sanitario and an existing farmaco / tecnovigilancia unit. They present this as avoiding the time to constitute a new Mexican company.
    • Agreement with distributors — one or several distributors on the record. They list the usual risks: commission disputes, contracts written for the distributor, and confidentiality / industrial-design leakage.

    FAQ facts they publish: they tell sponsors not to believe anyone who promises less than about 10 months after filing (they attribute current clocks to contingency backlog); sanitary registration validity is 5 years, then a prórroga; modifications include cesión de derechos, presentations, distributors, importers, and shelf life; as many distributors/importers as desired if each has its own aviso de funcionamiento. They say the work is done by RA specialists / pharmaceutical chemists who have worked inside COFEPRIS and/or Terceros Autorizados, and they claim review of around 500 expedientes with more than 95% success — those figures are theirs, not independently restated here as fact. They also work medicines, herbal remedies, cosmetics, supplements, non-alcoholic beverages, and foods. Devices are one of several product classes.

    What that product is — and is not

    REGULATE is a Mexico holder + dossier + import/publicity-permit shop. It is not a published 19-country subscription, not a holder that includes government fees and certified translations in one annual fee across LATAM, and not a trial-to-market CRO bridge. If Mexico is the only label, a homegrown “empresa estratégica” can be the right titular. If Mexico is one of five, the operating system matters more than the exact-match URL.

    COFEPRIS allows multiple importers and distributors on one registration. That is why the independent-holder model they describe is useful. Details and the equivalence route: Mexico COFEPRIS.

    REGULATE México vs bioaccess®

    Dimension REGULATE México bioaccess®
    Public product COFEPRIS representación legal / holder vs filial vs distributor LATAM Launch Subscription — register + hold already-cleared devices
    Who is the titular Their “empresa estratégica” already notified to COFEPRIS bioaccess® own Mexican entity, held for the manufacturer
    Product mix published Devices plus medicines, herbals, cosmetics, foods FDA-cleared / CE-marked medical devices
    Timeline they publish ~10 months post-filing; do not believe shorter promises Experience-based COFEPRIS class clocks and vía abreviada target; agency discretion reserved
    Multi-country Mexico page 19-market coverage; own entities; gov fees + certified translations included
    Holder as leverage Warns against distributor-as-titular Same doctrine, plus defined transfer provisions and a published IOR map

    The LATAM Launch Subscription from bioaccess® is a different product. bioaccess® registers already FDA-cleared (510(k)/PMA) or CE-marked devices and holds them through its own in-country entities — sanitary registration, registration holder / importer of record, certified Spanish or Portuguese translations (sworn where Brazil and Argentina require it), and government submission fees, inside one annual subscription per country and device family. Public coverage is described as 19 LATAM markets, with named pathways for ANVISA, INVIMA, COFEPRIS, ANMAT, ISP, DIGEMID, MINSA, ARCSA, DNM/SRS, and DIGEMAPS. The registration is held for the manufacturer’s benefit, with defined transfer provisions in the agreement; it is not leverage. Clinical-trial clients of bioaccess® receive the published Trial-to-Market Bridge (20% off the subscription). Specific rates are under review; contact bioaccess® for a quote. See the LATAM importer-of-record rules for how holder and importer split by country.

    When to use which

    Use REGULATE when the search is literally “holder Mexico COFEPRIS,” the catalog may include non-device health products, and there is no second regulator on the launch plan. Use bioaccess® when the same device family must be held in Mexico and in other LATAM markets under one subscription, when certified translations and government submission fees should not appear as surprise line items, and when the same partner already ran — or will run — the first-in-human study.

    If the plan is one country and a homegrown titular is enough, hire the shop that actually publishes that job. If the plan is several LATAM labels under one holder who is not the distributor, start at bioaccess® market access or request a registration quote.

  • RAF Consulting COFEPRIS Titular vs bioaccess® LATAM Launch Subscription

    Teams searching “RAF Consulting COFEPRIS” or “titular de registro México” are usually looking for an independent Mexico Registration Holder (MRH) — a Mexican legal entity that will sit on the COFEPRIS sanitary registration so a foreign manufacturer does not have to give the license to its first distributor. That is a real, one-country job. RAF Consulting publishes dedicated holder pages for it in Spanish and English. This article names that product fairly, then explains when a multi-country holder subscription from bioaccess® is the better fit.

    What RAF Consulting publishes

    RAF Consulting is a Mexico regulatory shop with a public titular de registro / Mexico Registration Holder offer. The Spanish page is rafconsulting.net/titular-registro.php; the English twin is rafconsulting.net/eng/registration-holder.php (both checked as indexed holder URLs on 23 August 2026). Public positioning: independent MRH, not a commercial distributor. The shop also publishes dossier work and a tecnovigilancia unit framed against NOM-240. The commercial contrast they themselves use is independent holder versus distributor-as-titular — the same contrast U.S. sponsors already hear from global RA brands.

    What those pages do not publish — and this is a finding, not an insult — is a multi-country LATAM holder subscription, government fees and sworn translations inside one annual fee, or a trial-to-commercialization bridge with the same operator. RAF is a Mexico titular. Treat it as one.

    Why Mexico needs a titular at all

    COFEPRIS issues the sanitary registration in the name of a Mexico-established establishment. The titular del registro carries legal responsibility for the product. A foreign manufacturer that is not constituted in Mexico must appoint someone who is. That someone can be (1) the manufacturer’s own Mexican filial, (2) an independent holder / “empresa estratégica” already notified to COFEPRIS, or (3) a commercial distributor that will also be the titular. Option 3 is still common. It is also how a registration becomes leverage: changing the commercial channel later usually means a cesión de derechos, a new dossier, or both.

    COFEPRIS can name multiple distributors and importers on a single registration. That is why an independent titular is useful: the manufacturer keeps the license and adds or drops commercial partners without handing them the asset. See Mexico — COFEPRIS medical device registration and the importer-of-record guide.

    Mexico also has an equivalence route (vía abreviada) for devices already approved and marketed by the same manufacturer in a reference country (U.S. FDA, Health Canada, or Japan). A CE mark alone does not qualify. bioaccess® manages Class I–III COFEPRIS work on that pathway and on the standard route. Typical published processing targets (~30 / ~35 / ~60 working days by class; ~30 working days on the equivalence target) are routinely exceeded in practice; COFEPRIS retains full technical discretion. Approval is never guaranteed.

    RAF Consulting vs bioaccess®

    Dimension RAF Consulting bioaccess®
    Public product Independent Mexico MRH / titular de registro + dossier + tecnovigilancia LATAM Launch Subscription: register + hold already-cleared devices
    Geography published Mexico / COFEPRIS 19 LATAM markets; own in-country entities; country pages for Mexico, Brazil, Colombia, Argentina, Chile
    Who holds the license RAF as independent titular (their pages) bioaccess® through its own Mexican entity, for the manufacturer’s benefit
    Distribution Positions as not the distributor Holder is not the commercial distributor; registration is not leverage
    Gov fees + certified translations Not published as one included annual bundle Included in the annual subscription (sworn where required)
    Trial-to-market Not a published FIH CRO + holder bridge Trial-to-Market Bridge 20% for clinical-trial clients of bioaccess®

    The LATAM Launch Subscription from bioaccess® is a different product. bioaccess® registers already FDA-cleared (510(k)/PMA) or CE-marked devices and holds them through its own in-country entities — sanitary registration, registration holder / importer of record, certified Spanish or Portuguese translations (sworn where Brazil and Argentina require it), and government submission fees, inside one annual subscription per country and device family. Public coverage is described as 19 LATAM markets, with named pathways for ANVISA, INVIMA, COFEPRIS, ANMAT, ISP, DIGEMID, MINSA, ARCSA, DNM/SRS, and DIGEMAPS. The registration is held for the manufacturer’s benefit, with defined transfer provisions in the agreement; it is not leverage. Clinical-trial clients of bioaccess® receive the published Trial-to-Market Bridge (20% off the subscription). Specific rates are under review; contact bioaccess® for a quote. See the LATAM importer-of-record rules for how holder and importer split by country.

    When RAF is the right hire

    Hire a Mexico-only independent MRH when the commercial plan is Mexico, the manufacturer wants a homegrown COFEPRIS face, and there is no second-country clock. RAF’s public pages are built for that search. Hire bioaccess® when Mexico is the first of several labels — Brazil ANVISA, Colombia INVIMA, Argentina ANMAT, Chile ISP, Peru DIGEMID, and the rest of the published 19-market coverage — and the manufacturer wants one operator, one annual fee shape, and a holder who will not become the commercial channel.

    If the plan is one country and a homegrown titular is enough, hire the shop that actually publishes that job. If the plan is several LATAM labels under one holder who is not the distributor, start at bioaccess® market access or request a registration quote.

  • Registro sanitario de dispositivos médicos en LATAM: titular vs. distribuidor

    El registro sanitario de un dispositivo médico en América Latina no es un trámite de aduana ni un contrato de distribución. Es un acto administrativo: la autoridad sanitaria emite un certificado a nombre de una persona jurídica en el país. Esa persona es el titular (o detentor, o registration holder). En varios mercados esa misma persona — o una licencia pegada a ella — es también el importador de registro. Si el titular es su distribuidor, el registro es palanca comercial. Si el titular es un especialista independiente, usted puede cambiar de canal sin rehacer el expediente… siempre que el contrato prevea la cesión.

    Esta página es un hub de categoría, no un ataque a un competidor. Explica la diferencia entre titular e importador/distribuidor, nombra las autoridades que bioaccess® publica, y apunta al producto correcto: la LATAM Launch Subscription. Siempre bioaccess®. No hay clientes inventados, ni correos, ni listas de países que no estén en las páginas públicas de bioaccessla.com.

    Titular vs. distribuidor: la pregunta que evita el secuestro del registro

    El fabricante extranjero casi nunca puede figurar solo en el certificado. Cada regulador ata el registro a una entidad local:

    • Titular / detentor / registration holder. Es el nombre en el registro. Responde ante la autoridad por el expediente, las modificaciones y, en la práctica, por buena parte de la vigilancia post-comercialización.
    • Importador de registro (IOR). Es quien puede nacionalizar el producto. En algunos países el titular puede autorizar varios importadores sobre el mismo registro. En otros, titular e importador son la misma persona y no hay segundo IOR.
    • Distribuidor comercial. Vende, factura, da servicio. No tiene por qué ser el titular. Cuando lo es, cambiar de canal implica una cesión formal — o un registro nuevo.

    La doctrina correcta, y la que bioaccess® opera, es: el titular es un especialista independiente, con entidad propia, y el contrato trae una ruta de transferencia. El registro no es rehén. Las reglas por país — multi-importador frente a IOR único — están en la guía Importer of Record en LATAM.

    Ejemplos públicos de esa geometría (no es una lista inventada; es el mapa ya publicado):

    • México (COFEPRIS), Colombia (INVIMA), Brasil (ANVISA). Un titular puede articular varios importadores sobre un mismo registro, con matices de cada norma.
    • Argentina (ANMAT). El representante / titular es, en la práctica, el único importador de ese registro.
    • Perú (DIGEMID). Importación a través de droguería licenciada; el titular independiente es posible bajo el marco vigente citado en la guía IOR.

    Si un “socio local” le ofrece “yo registro y yo vendo,” pida por escrito: (1) razón social que figurará como titular, (2) si esa sociedad es suya o de un tercero, (3) cómo se cede el registro si termina el contrato, (4) quién paga tasas gubernamentales y traducciones certificadas.

    Qué incluye el registro — y qué suele facturarse aparte

    Un expediente de dispositivo ya autorizado por FDA (510(k)/PMA) o con marcado CE no se “copia y pega” en Latinoamérica. Hay vía de equivalencia o reliance en algunos mercados (por ejemplo, la vía abreviada de COFEPRIS cuando el dispositivo es del mismo fabricante y ya está aprobado y comercializado en un país de referencia). Hay notificación frente a registro en ANVISA según clase. Hay registro automático frente a revisión previa en INVIMA según clase. Esos relojes son de la agencia. El trabajo del titular es el expediente, el idioma, las tasas y la representación.

    Tres partidas que los consultores globales suelen dejar fuera del honorario y que bioaccess® mete en la suscripción anual por país y familia de dispositivo:

    • Tasas gubernamentales de presentación.
    • Traducción certificada (y jurada donde aplica, Brasil y Argentina) de IFU, etiquetas y expediente técnico — en casa, no como markup de una agencia.
    • Agente / titular local y la gestión de la sumisión.

    La tarifa específica de bioaccess® está en revisión — solicite una cotización. El hub publica descuentos multi-país y el Trial-to-Market Bridge para clientes de ensayo clínico. Fuera de cualquier tarifa plana honesta quedan la auditoría BGMP de planta en Brasil y la homologación telecom/EMC-RF de dispositivos inalámbricos; se gestionan y se facturan a costo de proveedor más G&A publicado. Detalle: bioaccessla.com/market-access.

    Autoridades que bioaccess® nombra en público

    Seis mercados núcleo, con página propia o bloque en el hub: Brasil (ANVISA), Colombia (INVIMA), México (COFEPRIS), Argentina (ANMAT), Chile (ISP), Perú (DIGEMID). La misma página de market access nombra también MINSA (Panamá), ARCSA (Ecuador), DNM/SRS (El Salvador) y DIGEMAPS (República Dominicana), y describe cobertura en 19 mercados de LATAM (lista completa a solicitud). No se añaden países aquí que no estén en esas páginas.

    bioaccess® no obtiene el 510(k), el PMA ni el marcado CE por usted. El producto es el registro sanitario en LATAM de un dispositivo ya autorizado en esos marcos de referencia, más la tenencia del certificado a través de entidades propias.

    Garantía de sumisión, no garantía de aprobación

    La autoridad controla el dictamen. bioaccess® controla su trabajo: expediente completo presentado, en español o portugués certificado, con tasas pagadas, en la fecha comprometida. Si falla lo que controla, acredita una porción de la tarifa anual de ese país. Términos completos en la propuesta. Eso es la Submission Guarantee. No es una promesa de que COFEPRIS, ANVISA o INVIMA aprueben.

    Cómo elegir titular sin confundirlo con la CRO

    El ensayo clínico first-in-human y el registro comercial son actos distintos. Se puede — y suele — usar el mismo socio de confianza para no reaprender el expediente, y eso es el Trial-to-Market Bridge de bioaccess®. No contrate un titular de registro como si fuera la CRO del implante, ni una CRO de fase III de fármaco como si fuera su detentor ANVISA. Producto distinto, contrato distinto, a veces la misma firma.

    1. Pida la razón social local que firmará como titular en cada país.
    2. Pida si esa sociedad es propia o una red de partners.
    3. Pida la cláusula de cesión.
    4. Pida la lista de inclusiones: tasas, traducción jurada, respuestas a requerimientos, renovación.
    5. Pida el remedio si el vendor atrasa la sumisión que él controla.

    Preguntas frecuentes — registro sanitario de dispositivos médicos en LATAM

    ¿Qué es el titular de un registro sanitario?

    La persona jurídica local a cuyo nombre la autoridad emite el certificado. No es, por definición, el distribuidor.

    ¿Puedo usar mi distribuidor como titular?

    En muchos mercados es legal. Es una mala arquitectura si usted quiere cambiar de canal. Prefiera un titular independiente con cesión definida.

    ¿bioaccess® es el titular en Latinoamérica?

    bioaccess® registra y sostiene el dispositivo a través de sus propias entidades locales, con disposiciones de transferencia en el acuerdo. Cobertura descrita como 19 mercados; detalle en el hub de market access.

    ¿Cuánto cuesta?

    Suscripción anual plana por país y familia de dispositivo. Las tarifas específicas están en revisión — solicite una cotización. Tasas gubernamentales y traducciones certificadas van incluidas.

    ¿Dónde empiezo?

    Market access, IOR, contacto o agenda.

    Hechos de bioaccess®: bioaccessla.com/market-access y bioaccessla.com/latam-importer-of-record (revisión julio 2026). Página de categoría, no comparativo de un competidor nombrado. Sin clientes, correos, estadísticas ni países inventados. Consultado 23 de agosto de 2026.

  • Freyr vs bioaccess®: LATAM Device Registration and the Brazil Registration Holder

    Freyr Solutions publishes a dedicated “medical device registration in LATAM” hub. That page is why this article exists. A manufacturer searching “LATAM device registration” or “Brazil Registration Holder” will see Freyr and bioaccess® in the same cluster. Freyr is a global regulatory-affairs firm with a LATAM device offering. bioaccess® is the LATAM holder subscription. Both can be on an RFP. They should not be scored as the same SKU.

    Tone first: Freyr is a legitimate global RA shop. If you need a worldwide dossier machine and you already buy Freyr for other regions, keep them. If you need an in-country titular who includes government fees and certified translations in one annual fee, holds through own entities, and will still be there if the next milestone is a LATAM trial, that is bioaccess®.

    What Freyr publishes about LATAM devices

    The LATAM registration page is freyrsolutions.com/medical-devices/medical-device-registration-in-latam. It states a “strong presence in Brazil, Mexico, and Colombia.” The medical-device market-access hub lists Brazil (ANVISA), Mexico (COFEPRIS), Argentina (ANMAT), and Colombia (INVIMA). Country microsites exist at freyrsolutions.com.br and freyrsolutions.com.mx. Those are the public geography claims used here. No extra countries are added.

    The Brazil Registration Holder page is the sentence that matters for this comparison. Freyr writes that it acts as the BRH — liaison / agent language, “Act as the BRH” — and that it has an extensive partner network across Brazil. Read both halves. “We act as BRH” is a holder claim. “Partner network across Brazil” is a network claim. A manufacturer should ask, in writing, which local CNPJ will be the detentor de registro on this file, and whether that company is Freyr-owned or a partner. Transfers in Brazil require the current holder’s cooperation; Freyr’s own materials warn that changing BRH is not a casual email.

    The Mexico language on the public medical-device pages is coordination with the registration holder and the local legal representative. That is not the same sentence as “Freyr is your Mexico Registration Holder.” Treat Mexico as RA coordination unless a signed SOW names Freyr (or a named Freyr Mexico entity) as titular. Argentina is listed on the market-access hub as ANMAT; that is a listed market, not automatically a published AAR-owned-entity claim.

    Commercial model, as published: “cost-effective annual support for BRH Service.” That is annual holder support, not an all-in government-fee-plus-certified-translation subscription. “Approved translation” appears as a challenge on Freyr’s LATAM materials, not as an included in-house factory. The marketing KPI “99%+ first-time-right” is a quality statistic. It is not a fee-credit guarantee if the vendor misses a submission date it controls. No Trial-to-Market Bridge (LATAM FIH CRO + commercial registration) is published. Facts from Freyr’s public medical-device pages, retrieved 23 August 2026. No clients or emails added.

    BRH is a legal person, not a slide

    ANVISA issues the registro or notificação to a detentor de registro. That company is on the hook for post-market obligations and for authorizing importadores (RDC 751/2022; importers can be added without re-registering the device under the rules summarized on the IOR guide). If the detentor is a partner in a network, you have a competent local face and a second contract to unwind later. If the detentor is the vendor’s own Brazilian company, you have one throat to choke and a cleaner transfer covenant — provided the covenant is actually in the agreement.

    bioaccess® holds LATAM registrations through its own in-country entities for the manufacturer’s benefit, with defined transfer provisions so the file is not leverage. Brazil is one of the six core markets detailed on the ANVISA country page. The LATAM Launch Subscription puts government submission fees and certified Portuguese (sworn where required) inside the annual fee. Brazil BGMP site audit remains outside any honest flat fee and is billed at vendor cost plus published G&A — that carve-out is on the hub, not hidden.

    Freyr vs bioaccess®

    Dimension Freyr Solutions (public) bioaccess®
    Product Global RA / market access; LATAM device-registration hub; annual BRH support LATAM Launch Subscription: sanitary registration + holder / IOR
    Public LATAM footprint “Strong presence” BR / MX / CO; hub lists ANVISA, COFEPRIS, ANMAT, INVIMA 19-market coverage; hub details BR, CO, MX, AR, CL, PE and names MINSA, ARCSA, DNM, DIGEMAPS
    Brazil Registration Holder Freyr acts as BRH and cites a partner network across Brazil — ask which model applies to your CNPJ Own-entity holder; transfer provisions in the agreement
    Mexico Public language: coordination with the registration holder / local legal representative bioaccess® as independent titular / IOR on the COFEPRIS workstream
    Bundle Annual BRH support; gov fees + certified translations not published as one all-in family fee Government submission fees + certified translations included
    Translation Listed as a challenge (“approved translation”), not as included in-house production In-house; sworn where required; manufacturer owns the translation memory
    Guarantee language “99%+ first-time-right” = marketing KPI, not a fee-credit remedy Submission Guarantee: we credit a portion of that country’s annual fee if we miss the submission workmanship we control (full terms in the proposal)
    Pricing Project / line-item plus annual BRH support; no public all-in LATAM subscription Flat annual subscription per country / device family; rates under review — contact for a quote
    Trial-to-Market Bridge Global RA, not a published LATAM FIH CRO Same partner from LATAM trial to commercial registration

    When Freyr is the better fit

    • You want a global RA firm for a worldwide submission calendar, and LATAM is one region on that calendar.
    • You specifically want Freyr’s BRH annual-support product and you have confirmed, in writing, whether the detentor is Freyr or a partner.
    • You will buy translations and government fees as separate lines and you are comfortable with a first-time-right KPI instead of a fee-credit clause.
    • Your live LATAM set is the BR / MX / CO presence (plus ANMAT as listed) and you do not need the rest of the 19-market holder map on day one.

    When the LATAM Launch Subscription is the better fit

    • The buying criterion is “who is on the certificate,” not “who can coordinate a holder.”
    • You want government fees and certified translations inside the annual fee.
    • You want a Submission Guarantee that can credit fee, not only a 99%+ statistic.
    • You need holder / IOR beyond the four regulators Freyr lists, or you need the multi-importer vs single-IoR map.
    • You want the Trial-to-Market Bridge.

    Read market access, IOR, Brazil, Mexico, Colombia, Argentina. Compares already live: vs Emergo by UL, vs Qserve.

    What to ask Freyr (and any global RA shop) before you sign a BRH

    1. Name the Brazilian company that will be the detentor. Employee count in São Paulo is not the answer.
    2. Is that company Freyr-owned or a partner? Who signs the transfer if we leave?
    3. On Mexico: will Freyr be the titular, or will Freyr coordinate a third-party holder?
    4. Are ANMAT filings done as AAR, or is Argentina a project-management line?
    5. Itemize government fees and sworn translations. If they are extra, put them in the comparison total.
    6. What happens commercially if a first-time-right miss is the vendor’s workmanship? A KPI slide is not a credit.

    bioaccess® pricing stays under review — contact for a quote. Do not treat typical-competitor ranges on the hub as a Freyr quote; they are category context, not this firm’s invoice.

    FAQ — Freyr LATAM / BRH

    Does Freyr register medical devices in LATAM?

    Yes, on its dedicated LATAM device-registration page. It claims a strong presence in Brazil, Mexico, and Colombia and lists ANVISA, COFEPRIS, ANMAT, and INVIMA on the market-access hub.

    Does Freyr act as Brazil Registration Holder?

    The BRH page says Freyr acts as the BRH and also cites a partner network across Brazil. Confirm which model applies to your registration.

    Is Freyr the Mexico Registration Holder on the public page?

    The public Mexico language reviewed here is coordination with the holder and local legal representative. Do not assume Freyr is the titular until the SOW says so.

    Is “99%+ first-time-right” a Submission Guarantee?

    No. It is a marketing KPI. bioaccess®’s Submission Guarantee is a workmanship remedy that can credit a portion of that country’s annual fee. Full terms in the proposal. Neither firm can guarantee agency approval.

    Is this a smear of Freyr?

    No. Freyr is a global RA firm. The distinction is product: annual BRH support and LATAM coordination versus a LATAM-only all-in holder subscription.

    Where should a sponsor start?

    Market access, IOR, contact.

    Sources for competitor facts: freyrsolutions.com medical-device LATAM, market-access, and Brazil Registration Holder pages (plus .br / .mx medical-device microsites), retrieved 23 August 2026. bioaccess® facts: bioaccessla.com/market-access and bioaccessla.com/latam-importer-of-record. No invented clients, emails, statistics, or country lists.

  • MedEnvoy vs bioaccess®: Mexico Registration Holder and the Rest of LATAM

    “Mexico Registration Holder” is a job title, not a brand. When a manufacturer types that string, MedEnvoy and bioaccess® are both allowed to appear. MedEnvoy is a specialist in-country representative (ICR) firm. bioaccess® is the LATAM holder subscription. They overlap in Mexico, Colombia, Peru, and Brazil. They do not overlap as products.

    This page names MedEnvoy from its public site, then maps the rest of Latin America. MedEnvoy is a reasonable independent holder in the four LATAM markets it actually publishes. It is not, on the public record, an all-in 19-market subscription with government fees and certified translations inside one annual fee. That is the bioaccess® job.

    What MedEnvoy publishes about itself

    MedEnvoy’s site is medenvoyglobal.com. The firm presents as a global in-country representation specialist, founded in the Netherlands, independent of distributors. The homepage service picker and the in-country-representation section list four LATAM products by name: Mexico Registration Holder, Colombian Registration Holder, Peru Registration Holder, and Brazil Registration Holder. Dedicated pages exist for those four:

    Argentina appears in translation-related content, not as a published Argentina Authorized Representative product page on the pages reviewed 23 August 2026. Do not invent an AAR service MedEnvoy has not posted.

    Independence from distributors is the core pitch, especially on the Mexico page: the manufacturer keeps the sanitary registration and can appoint or change commercial partners without handing them the titular role. That is the correct doctrine. Transfer of a COFEPRIS registration is still a formal process; MedEnvoy says so. The Brazil, Colombia, and Peru pages explain the legal role and invite coordination. They do not, on those pages, quote a named local CNPJ or RFC. ISO 13485 is claimed for the firm on the public about / quality language.

    Pricing is quote-driven. There is no public all-in LATAM Launch-style subscription that includes government fees and sworn translations in one annual number. Translations show up as a compliance topic (including blog treatment), not as an in-house factory bundled into the holder fee. No Submission Guarantee equivalent and no trial-to-commercial LATAM CRO bridge appear on the public pages reviewed. Facts above are from MedEnvoy’s public site, 23 August 2026. No clients or emails are added.

    Mexico is not “the rest of LATAM”

    COFEPRIS is the query that pays for a lot of ICR marketing, and for good reason. Mexico is a large device market, the equivalence route (vía abreviada) is real for devices already approved and marketed by the same manufacturer in a reference country, and the Mexico Registration Holder can name multiple distributors and importers on one sanitary registration. That last point is why an independent MRH is worth buying: you can add a second importer without restarting the file. See the country rules on the LATAM Importer of Record guide and the COFEPRIS country page.

    The mistake is to treat a four-country ICR menu as a Latin American operating system. A manufacturer that clears Mexico still has to answer, country by country:

    • Who is the titular in Colombia (INVIMA — a titular can have several importers)?
    • Who is the detentor de registro in Brazil, and who are the authorized importadores?
    • Who is the fused holder-and-importer in Argentina (ANMAT — one AAR per registration)?
    • Who holds Chile (ISP), Peru (DIGEMID / droguería rules), Panama (MINSA), Ecuador (ARCSA), El Salvador (SRS), Dominican Republic (DIGEMAPS), and the other markets on a 19-country plan?

    MedEnvoy publishes holder pages for MX, CO, PE, and BR. That is a real four-market ICR product. It is not a published ANMAT, ISP, MINSA, ARCSA, DNM/SRS, or DIGEMAPS holder product. bioaccess® publishes the LATAM Launch Subscription as coverage across 19 LATAM markets, with six core markets detailed on the hub and those additional regulators named on the same page. Own in-country entities hold the files, with defined transfer provisions so the registration is not hostage.

    MedEnvoy vs bioaccess® — same contrast axes

    Dimension MedEnvoy (public) bioaccess®
    Product Global ICR / registration-holder specialist; independent of distributors LATAM Launch Subscription: register + hold already-cleared devices
    Public LATAM holder pages Four: Mexico, Colombia, Peru, Brazil 19-market coverage; hub details BR, CO, MX, AR, CL, PE; also names MINSA, ARCSA, DNM, DIGEMAPS
    Independence / anti-leverage Core pitch — do not let the distributor hold the registration Same doctrine, plus own entities and written transfer provisions
    Bundle (gov fees + certified translations) Not published as an all-in annual inclusion Included in the annual subscription per country / device family
    In-house translation Discussed as compliance / blog topic, not as included production In-house certified Spanish/Portuguese; sworn where required; translation memory is the manufacturer’s property
    Pricing model Quote-driven; no public all-in LATAM subscription Flat annual subscription; rates under review — contact for a quote. Multi-country and Trial-to-Market Bridge discounts as published on the hub
    Quality claim ISO 13485 claimed Operating model published on the market-access hub (track record is self-reported as of July 2026)
    Submission Guarantee None found on the public pages reviewed Submission workmanship: dossier in, certified language, government fees paid, on the committed schedule, or a portion of that country’s annual fee is credited (full terms in the proposal)
    Trial-to-Market Bridge Not a LATAM FIH CRO Same partner from trial to commercial registro sanitario

    When MedEnvoy is the better fit

    • You want a dedicated global ICR, not a LATAM-only subscription, and Mexico / Brazil / Colombia / Peru is the live set.
    • Independence from distributors is the only buying criterion and you will run translations and government fees as separate vendors.
    • You already use MedEnvoy as ICR in other regions and want one representative brand on the org chart.
    • You need ISO 13485 language on the ICR itself and you are buying a quote, not a published bundle.

    Hire them for that. Do not hire them for a job they have not published — for example, “titular in 19 LATAM markets with sworn translations inside one fee.”

    When bioaccess® is the better fit

    • Mexico is the first country, but Argentina, Chile, Panama, Ecuador, El Salvador, or the Dominican Republic is already on the 12-month plan.
    • You want government fees and certified translations inside the annual fee.
    • You want the holder to be bioaccess®’s own local entity, with transfer language, including the IOR variants (multi-importer vs single-IoR) documented on the IOR guide.
    • You want a Submission Guarantee on submission workmanship.
    • You want the Trial-to-Market Bridge — the same firm that can run the LATAM trial can hold the commercial file.

    Start at the market-access hub. Country deep-dives: Mexico, Brazil, Colombia, Argentina, Chile. Existing global compares: vs Emergo by UL, vs Qserve.

    Questions to put in the MedEnvoy (or any ICR) RFP

    1. Name the local legal entity that will be the COFEPRIS / INVIMA / ANVISA / DIGEMID holder. Is it MedEnvoy-owned or a partner?
    2. Which LATAM countries beyond MX / CO / PE / BR are in scope on a written SOW — and which are “we can introduce someone”?
    3. Are government fees and sworn translations included, estimated, or excluded?
    4. What is the transfer covenant if we change ICR or stand up our own entity?
    5. Who owns the translation memory?
    6. Is there a fee-credit remedy if the vendor misses a submission date it controls?

    bioaccess® answers those from the published subscription. Pricing is under review — contact for a quote.

    FAQ — MedEnvoy Mexico Registration Holder / LATAM

    Is MedEnvoy a Mexico Registration Holder?

    Yes, on its own public page. It sells an independent MRH, separate from the distributor.

    Which other LATAM holder pages does MedEnvoy publish?

    Colombia (INVIMA), Peru (DIGEMID), and Brazil (ANVISA). Four public LATAM markets. Argentina is not treated here as a published AAR product page.

    Does MedEnvoy publish an all-in LATAM subscription?

    No. Pricing is quote-driven on the public record reviewed 23 August 2026.

    Does ISO 13485 make MedEnvoy the LATAM holder?

    It is a quality claim for the firm. It is not a substitute for own-entity coverage, included government fees, or a transfer covenant.

    Is this a smear?

    No. MedEnvoy is a specialist ICR. The distinction is product: four published LATAM holder pages and a quote, versus a 19-market LATAM subscription with translations and government fees in.

    Where should a sponsor start?

    Market access, IOR guide, contact.

    Sources for competitor facts: medenvoyglobal.com (homepage, about, ICR hub, MX / BR / CO / PE holder pages), retrieved 23 August 2026. bioaccess® facts: bioaccessla.com/market-access and bioaccessla.com/latam-importer-of-record. No invented clients, emails, statistics, or country lists.

  • Pure Global vs bioaccess®: Flat-Fee LATAM Device Registration and What Is Inside the Fee

    When a U.S. or EU medtech team searches “flat-fee medical device registration,” “ANVISA license holder,” or “COFEPRIS Mexico Registration Holder,” Pure Global and bioaccess® can land on the same shortlist. That is not an accident. Both firms sell an independent in-country holder for already-cleared devices, and both talk about an annual fee instead of a one-off consulting SOW.

    They are still different products. Pure Global is a global market-access firm with a published flat annual fee that starts at USD $2,000 per year and, on its own 5 February 2026 press release, leaves government fees, certified translations, and marketing materials outside that fee. bioaccess® is the LATAM holder subscription: sanitary registration, own-entity holder / importer of record, certified translations, and government submission fees inside one annual fee per country and device family, with a Submission Guarantee and a Trial-to-Market Bridge for clinical-trial clients. This page is a practitioner comparison, not a smear. Pure Global is a reasonable global RA / holder option in the markets it actually names. bioaccess® is the LATAM-only holder subscription.

    What Pure Global publishes about itself

    Pure Global’s public site is pureglobal.com. The firm positions local companies as authorized representative / license holder and publishes dedicated market pages for Argentina, Brazil, Colombia, Costa Rica, Mexico, and Peru (plus North America). On the Brazil, Mexico, and Colombia pages it sells the classic holder roles: Brazilian Registration Holder (BRH), Mexico Registration Holder (MRH), and INVIMA Legal Representative (with CCAA importer language on the Colombia page).

    Public entity language is strongest in those three markets. Pure Global names its own local companies in Brazil, Mexico, and Colombia — including Pure LATAM Colombia SAS (Bogotá), Pure Latam Mexico, S. de R.L. de C.V. (Mexico City), and a São Paulo office. The Peru page is more careful: it refers to “our local partner” while still using “Acting as your Holder.” Treat Peru — and, unless a named subsidiary appears, Argentina and Costa Rica — as partner-network coverage, not proven own-entity holder. That distinction matters when the registration is the only legal hook you have in-country.

    The commercial motion that makes Pure Global the closest analog is the fee. The Mexico page publishes “Starting at $2,000/year” and a fee calculator. The 5 February 2026 PR Newswire release, “Pure Global Introduces Industry-First Flat-Fee Pricing Model for Full-Service Global MedTech Market Access” (PR 302680246), describes a standard multi-year flat annual fee per registration and names Brazil, Mexico, and Colombia among the markets. The same release is explicit about what sits outside the fee: government fees, certified translations, and marketing materials. AI-assisted dossier workflows appear on the site. Pure Global is not a first-in-human CRO, and this comparison is not a CRO comparison.

    Facts above are taken from Pure Global’s public market and company pages and the 5 February 2026 release, retrieved 23 August 2026. No clients, emails, or extra country names are added.

    What “flat fee” has to mean on a LATAM holder file

    A Latin American sanitary registration is not a consulting memo. The regulator issues the certificate to an in-country legal person. That person is the titular / detentor / registration holder. In several markets the same person, or a closely tied license, is also the importer of record. If the holder is your distributor, the registration is commercial leverage. If the holder is an independent specialist, you can change distributors without rewriting the entire file — provided the agreement actually allows a transfer.

    The cash cost of that file is not only the holder’s time. Government submission fees are real invoices. Certified or sworn translations of IFUs, labels, and the technical file are often the largest hidden line, especially in Portuguese (Brazil) and Spanish with sworn-translator rules (Argentina, and frequently Brazil). A “flat annual fee” that excludes those two items is still a subscription. It is not the same product as a subscription that includes them.

    bioaccess® publishes that product as the LATAM Launch Subscription on bioaccessla.com/market-access. The model is: register and hold an already FDA-cleared (510(k)/PMA) or CE-marked device; act as in-country registration holder and importer of record through own local entities; include certified Spanish/Portuguese translations (sworn where required) and government submission fees; hold across 19 LATAM markets (six core markets detailed on the hub — ANVISA, INVIMA, COFEPRIS, ANMAT, ISP, DIGEMID — with MINSA, ARCSA, DNM/SRS, and DIGEMAPS also named on the same page). Specific subscription rates are under review — contact for a quote. Multi-country discounts and a Trial-to-Market Bridge (20% off for clinical-trial clients, as published on the hub) sit on top of that structure. The LATAM Importer of Record guide is the country-rule companion.

    Two items sit outside the bioaccess® flat fee because they cannot be bundled honestly at a flat rate: Brazil BGMP manufacturing-site audit and telecom/EMC + RF homologation for wireless devices. Those are managed end-to-end and billed at vendor cost plus published G&A. That carve-out is on the market-access page. It is not the same carve-out as “government fees and certified translations extra.”

    Pure Global vs bioaccess® — what is inside the fee

    Dimension Pure Global (public) bioaccess®
    Product Global medtech market access; independent AR / license holder; AI dossier workflows LATAM Launch Subscription: sanitary registration + holder / IOR for already-cleared devices
    Public LATAM market pages Argentina, Brazil, Colombia, Costa Rica, Mexico, Peru Hub details Brazil, Colombia, Mexico, Argentina, Chile, Peru; coverage described as 19 LATAM markets; also names MINSA, ARCSA, DNM, DIGEMAPS
    Own local entity vs partner Own subsidiaries published for BR / MX / CO. Peru page: local partner. AR / CR not proven as own entities on the public pages reviewed Holds through own in-country entities; defined transfer provisions so the registration is not leverage
    Holder roles named BRH, MRH, INVIMA Legal Representative / CCAA importer language Registration holder / IOR across the LATAM set; country rules on the IOR guide
    Published fee Flat annual fee starting USD $2,000/year (Mexico page + 5 Feb 2026 PR) Flat all-inclusive annual subscription per country and device family; rates under review — contact for a quote
    Government submission fees Outside the published flat fee (PR) Included
    Certified translations Outside the published flat fee (PR) Included; in-house production; sworn where required (Brazil, Argentina)
    Marketing materials Outside the published flat fee (PR) Not sold as a creative-agency line; labels/IFU translation for the dossier is in the subscription
    Submission Guarantee No public equivalent found (dossier submitted on a committed schedule or a fee credit) Yes — submission workmanship; portion of that country’s annual fee credited if we miss what we control; full terms in the proposal
    Trial-to-Market Bridge Not a published FIH CRO + commercial registration stack Same partner from LATAM clinical trial to commercial registro sanitario (20% off for clinical-trial clients, as published)
    FIH CRO Not this product Separate live CRO practice; not what this page sells

    Read the table as a product map. If you need a global AR network and a published $2,000 starting number, Pure Global is a real option — just budget government fees and certified translations as extra, because they said so. If you need a LATAM holder who already put those two lines inside the annual fee, holds through own entities, and will still be the same firm if you ran (or will run) the trial in the region, that is bioaccess®.

    When Pure Global is the better fit

    • You want one global market-access vendor beyond LATAM and you are already buying their U.S./Canada or other-market stack.
    • You want a published starting price of $2,000/year and you are willing to pay government fees, certified translations, and marketing materials as separate invoices.
    • Your live markets are Brazil, Mexico, and/or Colombia, where Pure Global publishes own legal entities, and you do not need Andean / Southern Cone / Central American / Caribbean breadth on day one.
    • You want their AI dossier workflow as the primary production method.

    None of those are insults. They are scope. A global RA firm is allowed to be good at global RA.

    When the LATAM Launch Subscription is the better fit

    • The near-term milestone is commercial registro sanitario in Latin America, not a worldwide RA retainer.
    • You want government submission fees and certified translations inside the annual fee, not as change orders.
    • You want the holder to be an own local entity with a written transfer path — including markets where Pure Global’s public page still says “local partner.”
    • You need more than the six Pure Global LATAM market cards, or you need the importer-of-record rules (multi-importer vs single-IoR) documented country by country.
    • You already used, or will use, bioaccess® as the LATAM clinical-trial CRO and want one accountable partner through commercialization (Trial-to-Market Bridge).
    • You want a Submission Guarantee on the workmanship of the submission — not a promise that the agency will approve.

    How to run the RFP without inventing numbers

    1. Ask each vendor to list the LATAM countries where their own legal entity will be the titular, and the countries where a partner will. Demand the local company name.
    2. Ask for a written inclusion list: government fees, sworn translations (page count and languages), holder/IOR year one and renewal, agency queries, and transfer of the registration if you leave.
    3. Ask whether marketing-material production is in or out. Pure Global’s PR already answers “out.”
    4. Ask what happens if the dossier is late because of the vendor. A KPI is not a fee credit.
    5. Ask who holds the translation memory. bioaccess® publishes that the glossary is the manufacturer’s property.
    6. Do not treat “starting at $2,000” as all-in LATAM cost. Add the two excluded lines before you compare it to a bioaccess® quote.

    bioaccess® pricing remains under review — contact for a quote. Country pages and the compare set already live: Brazil / ANVISA, Mexico / COFEPRIS, Colombia / INVIMA, Argentina / ANMAT, Chile / ISP, vs Emergo by UL, vs Qserve Group.

    FAQ — Pure Global LATAM device registration

    Does Pure Global offer a flat annual fee?

    Yes, on its public Mexico page (starting at $2,000/year) and in the 5 February 2026 PR Newswire release. The same release states that government fees, certified translations, and marketing materials sit outside that fee.

    Does Pure Global act as BRH, MRH, or INVIMA Legal Rep?

    Those roles are on its Brazil, Mexico, and Colombia market pages. Own-entity language is published for those three countries. Peru is described with a local partner.

    Is Pure Global a first-in-human CRO?

    No. Do not hire it — or bioaccess®’s market-access team — as a substitute for an ISO 14155 FIH operating system. Commercial registration and investigational-device trials are different regulatory acts.

    What does bioaccess® include that the Pure Global flat fee excludes?

    On the published record: government registration submission fees and certified translations, plus own-entity holder across the 19-market LATAM coverage, a Submission Guarantee, and the Trial-to-Market Bridge. bioaccess® rates are under review — contact for a quote.

    Can a sponsor use both?

    Yes. A common pattern is a global RA firm for FDA/EU work and bioaccess® for LATAM holder / IOR. Documentation is built to reuse the FDA or CE technical file.

    Where should a sponsor start?

    Market access, IOR rules, then contact or book a meeting.

    Sources for competitor facts: pureglobal.com market and company pages and PR Newswire release 302680246 (5 February 2026), retrieved 23 August 2026. bioaccess® facts: bioaccessla.com/market-access and bioaccessla.com/latam-importer-of-record (July 2026 review). No invented clients, emails, statistics, or country lists.

  • COFEPRIS Medical Device Registration Checklist (Mexico): MRH, Abbreviated Pathway, and Spanish Dossier

    COFEPRIS medical device registration is the ranking laggard for a reason: most English pages either recycle a generic “LATAM registration” outline or talk about manufacturing in Mexico. U.S. RA leads need a holder checklist — who owns the registro sanitario, which pathway you actually qualify for in 2026, and what must be in Spanish before DIGIPRIS will take the fee.

    bioaccess® works from Miami with U.S. MedTech sponsors and keeps trial plus market-access coverage across 19 Latin American and Caribbean markets. Mexico is one market in that footprint, not the only one. Timelines below are experience-based planning ranges for 2026, not COFEPRIS SLAs.

    What COFEPRIS registration is

    COFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios) issues the sanitary registration that must appear on Mexican labeling before you commercially import and sell a device. The legal spine is the Ley General de Salud plus the device reglamento and the applicable NOMs — especially NOM-137-SSA1 (labeling) and NOM-241-SSA1 (GMP / good manufacturing and quality practices for devices). Classification is risk-based Class I / II / III (with IIa/IIb language used in some COFEPRIS materials). Classification drives dossier depth and the standard-route calendar.

    A 510(k), De Novo, PMA, or CE certificate is not a Mexican registration. Since September 2025 it can be the ticket onto the abbreviated / equivalence pathway if the authorization comes from an IMDRF- or MDSAP-recognized authority (FDA is the usual U.S. case; Health Canada, TGA, and EU MDR authorizations are the other names reviewers expect). That pathway is a summary dossier plus reliance — not a copy-paste of the FDA decision summary into a Spanish folder with no Mexican holder.

    The Mexico Registration Holder is the asset

    Foreign manufacturers do not hold the registro sanitario. A Mexico Registration Holder (MRH) — a legally constituted Mexican entity, sometimes still called the authorized representative or sanitary correspondent — files, pays the government fee, and typically owns the number in its name. Transfers are possible and slow. If your exclusive distributor is the MRH, a breakup is a regulatory project.

    • Notarized, apostilled letter of representation / power of attorney that states exactly what the MRH may file, modify, renew, and report.
    • MRH corporate standing and, where applicable, the establishment notices COFEPRIS expects for the activities they perform.
    • A written plan for who is importer of record vs. who is MRH vs. who is distributor. One company can wear two hats. Three hats on a thin distributor is how import permits stall when a person leaves.
    • Exit language: how you will transfer the registration if the commercial deal ends. Put it in the appointment, not in a slide.

    Pathways and a hedged calendar

    • Standard route. Full technical dossier. Published planning windows you will hear in 2026: on the order of 20–30 days for many Class I files, 30–60 for Class II, 60–180 for Class III — after a complete filing. Deficiency letters and workload stretch those numbers. Class III implants should not be promised as a 60-day launch.
    • Abbreviated / equivalence route (from 1 September 2025). Summary dossier that leans on a valid FDA or other recognized-market authorization. COFEPRIS has socialized a ~30-day target review across classes. Treat 30 days as a target after completeness, not as door-to-door from the day you hire counsel. Spanish labeling, the MRH pack, and “same device” identity (indications, design, manufacturer) are where abbreviated files die.

    March 2025 simplification measures trimmed some administrative steps and compressed certain low-risk reviews. They did not delete the holder requirement.

    Dossier checklist

    Every pathway

    • Device identity: generic and brand names, models, accessories, intended use, and the Mexican class you are claiming.
    • MRH letter of representation, apostilled; manufacturer corporate documents as required.
    • QMS evidence — ISO 13485 is the practical standard and is the usual way to speak to NOM-241 expectations. MDSAP or a recognized GMP certificate helps; “we are FDA-registered” alone is a thin story.
    • Spanish labels and IFU per NOM-137: generic name, origin, lot/serial, expiry if applicable, manufacturer, importer/MRH, and a reserved field for the registration number.
    • Proof of payment of the COFEPRIS government fee for the correct clave / modality. Fees are published in MXN and change. Do not freeze a USD “all-in” number from a 2023 blog post.

    Standard route extras

    • Full technical description, drawings, materials, and specifications.
    • Risk analysis (ISO 14971 or equivalent).
    • Biocompatibility, electrical, software, and sterility evidence that matches how the device is sold.
    • Clinical evidence appropriate to Class III and to novel Class II claims.

    Abbreviated route extras

    • Certified evidence of the foreign marketing authorization (FDA clearance/approval letter and current listing story, or the equivalent CE/MDR, Health Canada, TGA pack).
    • A “sameness” memo: indications, design, labeling claims, and legal manufacturer must match what the reference authority approved. A Mexico-only indication is not an abbreviated file.
    • Spanish summary of the foreign review story — not 400 pages of untranslated FDA correspondence.

    Validity, renewals, and technovigilance

    First registrations remain a five-year instrument in normal practice. As of January 2026, subsequent renewals can be granted for periods of up to ten years — useful if you are already on the market and your holder is stable. Technovigilance reporting stays with the MRH. If your U.S. complaint system does not forward Mexico-reportable events to the MRH on a defined clock, you have a regulatory gap, not a “local admin” task.

    FAQ-style close

    Can a U.S. company be the registration holder? Not without a Mexican legal entity acting as MRH. Plan the holder before you book the DIGIPRIS slot.

    Does the abbreviated pathway replace the MRH? No. It shortens the technical review when the foreign authorization is real and the device is the same. The holder still files.

    Is this the same as a COFEPRIS clinical-trial authorization? No. Research ethics and trial import of investigational units are a different authorization. Do not send a 510(k) equivalence pack to a trial desk and expect a sanitary registration number.

    How should we budget? Government fees are only the clave. Translations, apostilles, MRH retainers, and one likely deficiency cycle are the project. Hedge the calendar; do not sell the board a single flat USD fee.

    Where does a multi-country register-and-hold model live? If the devices are already FDA-cleared (510(k)/PMA) or CE-marked and you want an independent holder rather than a distributor-owned number, bioaccess® describes that separately on the LATAM Launch Subscription market-access page. Mexico is usually sequenced with the abbreviated pack and a holder who is not also your only commercial bet.

  • INVIMA Device Approval in Colombia: Registration Checklist

    INVIMA page-one rankings for “approval” still convert poorly when the article is about a clinical trial. This checklist is the other file: registro sanitario / market authorization for a medical device you intend to import and sell in Colombia — holder, importer, Spanish dossier, UDI — not a first-in-human CEI/INVIMA trial pack.

    bioaccess® is U.S.-anchored in Miami and supports U.S. MedTech sponsors on both clinical execution and market access across 19 Latin American and Caribbean markets. The ranges below are planning ranges from that work in 2026. They are not INVIMA guarantees, and they are not a promise that a new decree will freeze today’s clocks.

    What INVIMA registration is

    INVIMA (Instituto Nacional de Vigilancia de Medicamentos y Alimentos) is Colombia’s Level 4 PAHO/WHO authority and an IMDRF participant. Device market access still sits primarily on Decree 4725 of 2005 (devices) and Decree 3770 of 2004 (IVDs), with Resolution 1405 of 2022 driving UDI-DI and semantic reporting. A modernization decree to replace 4725 has been in motion through 2026 (IMDRF-aligned safety/performance language, ISO 13485 as the explicit GMP reference, personalized-device language). Until that decree is in force, plan against 4725 and treat “the new decree will save us a quarter” as speculation.

    Two structural facts U.S. RA teams get wrong. First, the manufacturer remains the owner of the sanitary registration even without a Colombian office — unlike Mexico, where the local holder typically owns the number. Second, you still cannot operate the file yourself: you appoint a Colombia-domiciled Legal Representative (representante legal) and you identify an importer that already holds a valid CCAA (Certificado de Capacidad de Almacenamiento y Acondicionamiento).

    Classification: uncontrolled vs controlled

    Colombia’s four-class scheme (I, IIa, IIb, III) tracks EU-style risk rules more closely than FDA’s three classes. Borderline products should be classified in Colombia, not copied from a 510(k) letter.

    • Uncontrolled (Class I and IIa). A complete application can receive immediate certificate issuance. You may import while INVIMA reviews the technical file after the number exists. That is not “no review.” Ignore a post-approval information request and the registration can be wound back.
    • Controlled (Class IIb and III). Full pre-market technical review. Practitioner calendars of 6–8 months of INVIMA time are common; 8–12 months start-to-number is a safer sponsor calendar once translations and CFS lead time are included. Clinical and performance evidence are expected, not optional appendices.

    Holder and importer checklist (do this before tramites.invima.gov.co)

    • Legal Representative appointment. Mandatory under 4725 for foreign manufacturers. The RL submits, receives oficio, and owns the response clock. Switching RL after approval is a formal modification, not a vendor swap.
    • Importer with a live CCAA. Storage and conditioning capacity is a licensed activity. Name the importer in the application. If your commercial distributor’s CCAA lapses, your import lane lapses with it.
    • Decide whether RL and importer are the same entity. Combining them is operationally simple and strategically sticky. Splitting them costs more coordination and protects you when the commercial relationship changes.
    • Keep manufacturer ownership visible in the power of attorney and in how labeling shows the legal manufacturer vs. the importer.

    Dossier checklist (Spanish, not “English plus a cover letter”)

    Evidence INVIMA actually blocks on

    • CFS or CFG from the country of origin or a recognized reference market (United States, Europe, Canada, Japan, Australia). This is the document that slips the calendar — FDA export certificates and notified-body paperwork have their own queues.
    • ISO 13485 (or equivalent QMS) covering the legal manufacturer and the device scope you are registering.
    • Technical file in Spanish: description, intended use, classification rationale, specifications, manufacturing overview.
    • Risk management consistent with ISO 14971 thinking.
    • Test reports expected for IIa and required in practice for IIb/III (bench, biocompatibility, electrical, software — whatever the device actually is).
    • Clinical evidence for IIb/III: investigation reports, clinical evaluation, or a literature-based CER that can survive a reviewer who has seen EU MDR files.
    • Spanish labeling and IFU, with space for the INVIMA registration number and the importer identity.
    • RL authorization / power of attorney and the importer’s CCAA evidence.

    UDI-DI and semantic reporting (2026 is not “upcoming”)

    Resolution 1405/2022 is in force. Holders obtain UDI-DI codes from a recognized issuing agency (GS1, HIBCC, ICCBBA, and the other agencies INVIMA lists) and complete semantic reporting on INVIMA’s platform. The deferred deadline for many Class I / IIa / Category I IVD records ran through early February 2026. If you already have a Colombian number and you have not closed UDI-DI plus the semantic report, treat commercialization as at risk — INVIMA has been explicit that noncompliant records should not be sold against. New registrations should build UDI into the launch pack, not a “phase 2.”

    Fees, validity, and the calendar

    INVIMA government fees are published in Colombian pesos and change. Recent practitioner tables put device application tariffs roughly in the COP 3.9–4.4 million band by uncontrolled vs. controlled pathway (IVDs somewhat lower). That is the state tariff, not the project. Legal-representative retainers, certified translations, and controlled-pathway deficiency cycles are the real budget. There is no honest single “$5,500 all-in Colombia registration” number that survives contact with a Class III implant and a stale CFS.

    Certificates are typically valid 10 years. File renewal on the order of three months before expiry. Technovigilance is continuous: serious incidents and field actions route through the RL into INVIMA’s program. Quarterly discipline beats a once-a-year “PMS cleanup.”

    FAQ-style close

    Is INVIMA registration the same as INVIMA clinical-trial authorization? No. Trial submissions, CEI/IRB, and import of investigational units are a different operating system. This checklist is for a device you will commercialize.

    Does FDA or CE mark create automatic INVIMA approval? No formal equivalency pathway like Mexico’s abbreviated route. A U.S. or EU CFS/CFG is mandatory evidence, not a stamp that skips the file.

    Who holds the number? The manufacturer owns the registration. The RL and the CCAA importer operate it. Write those contracts so a distributor change does not hold your sanitary registration hostage.

    Where does this sit in a multi-country launch? Colombia is often the Andean first filing because of the uncontrolled path for I/IIa and a 10-year certificate. Sequence CFS procurement first. If you already have FDA-cleared or CE-marked devices and want a register-and-hold model across LATAM rather than a one-off INVIMA project, the structured offer is on bioaccess®’s market-access / LATAM Launch Subscription page.

  • ANMAT Medical Device Registration Checklist (Argentina): Holder, HELENA Dossier, and 2026 Calendar

    If you searched “medical device registration in Argentina (ANMAT),” you are not looking for a first-in-human protocol. You are looking for a holder problem: who files in HELENA, who signs as legal representative and technical director, which Spanish dossier ANMAT actually reads, and how long the calendar runs after the Certificate of Free Sale leaves FDA or your notified body. This is that checklist — registration and market authorization, not an Argentine clinical trial.

    bioaccess® is a U.S.-anchored MedTech partner (Miami) that works with U.S. sponsors across trials and market access in 19 Latin American and Caribbean markets. Argentina is one of those markets. The notes below are experience-based planning ranges for 2026, not guaranteed clocks or a government fee table you can paste into a board deck without checking ANMAT’s current aranceles.

    What ANMAT registration is (and is not)

    ANMAT (Administración Nacional de Medicamentos, Alimentos y Tecnología Médica) records devices in the Registry of Producers and Products of Medical Technology (RPPTM / RPPMT). The backbone remains the Mercosur registration framework (GMC Res. 40/00, incorporated via Disposición 2318/02) plus later ANMAT dispositions — including 727/2013, 9688/2019, 11467/2024, and the 2025–2026 modernization package (notably Disposición 64/2025, 8799/2025, and 4446/2025). HELENA is the electronic product-registration portal. GEMHA is the establishment-enablement track for manufacturers and importers. Those are different queues. Mixing them is a common calendar killer.

    A U.S. 510(k), PMA, or CE mark does not become an Argentine registration. It becomes evidence — typically a Certificate of Free Sale / Certificate to Foreign Government from a recognized reference market — that your in-country holder attaches to a Spanish dossier. ANMAT still classifies the product under its own Class I–IV (devices) or A–D (IVD) rules and still reviews what you filed.

    The bottleneck is the holder, not the PDF

    A foreign manufacturer without an Argentine legal entity must appoint an Argentina Authorized Representative (AAR). The AAR is the registration holder and ANMAT’s only official counterpart. A Technical Director (director técnico) must also be named. HELENA filings are PDFs digitally signed by both. If you appoint your exclusive distributor as AAR, you have just tied the sanitary registration to a commercial contract. Changing distributors later is a transfer, not a courtesy email.

    Importer-of-record is a related but separate role. Low-risk import rules moved in 2025 (Disposición 4446/2025): many Class I/II shipments shifted from per-shipment authorization toward a sworn notification model. Class III/IV and used/refurbished product (Disposición 224/2026) still need prior thinking. Do not assume the AAR, the IOR, and the commercial distributor are the same company unless you designed it that way.

    Classification and pathway (plan the calendar here)

    • Class I / II — Declaration of Conformity route. Administrative review of a DoC plus supporting file. Published ANMAT review windows are often cited at 15–30 working days after a complete HELENA package. End-to-end calendar (translations, apostilles, AAR enablement, deficiency loops) is commonly 60–120 working days in practice.
    • Class III / IV — full technical review. Safety, performance, GMP evidence, risk file. Published review windows are often cited at 60–110 working days. Sponsors who treat that as “three months to first sale” under-plan. Deficiency rounds and GMP questions routinely push the working calendar toward a year for higher-risk implants.
    • IVDs. Separate classification (A–D) and a review window often cited at 60–90 working days. Do not reuse a device Class I playbook on a Class C infectious-disease assay.

    Before formal review, the Medical Device Registry office typically runs a completeness check (about 10 consecutive days). Incomplete HELENA uploads reset the clock. That is the cheapest delay to avoid.

    Dossier checklist for the Argentine holder

    Legal and holder pack

    • AAR appointment / power of attorney, apostilled (or consularized) and translated by a certified public translator (traductor público) where required.
    • Manufacturer incorporation evidence and manufacturing-site list that matches the CFS and ISO certificate.
    • Technical Director identification and digital-signature readiness in HELENA.
    • GEMHA (or applicable establishment) enablement if the importer/AAR is not already habilitated for your product type. Disposición 8799/2025 created a simplified sworn-declaration track (THEMIS) for some low-risk establishments — confirm whether you actually qualify before you skip GEMHA.

    Technical pack (class-dependent)

    • Spanish device description, intended use, and ANMAT classification rationale (do not paste the FDA product code and hope).
    • Certificate of Free Sale / CFG from a recognized authority (commonly U.S., EU, Canada, Japan, or Australia), recent enough for ANMAT’s “issued within the last 24 months” style expectation, apostilled.
    • ISO 13485 / GMP evidence. ANMAT-MDS is aligned with ISO 13485:2016; a current certificate covering the exact legal manufacturer and scope beats a generic brochure.
    • Risk-management file (ISO 14971) — expected for Class II+ and for implants, IUDs, and blood bags even when the class looks “low.”
    • Essential safety and performance evidence under current ANMAT rules (see Disposición 11467/2024), plus test reports appropriate to class.
    • Labeling and IFU in Spanish, mapped to ANMAT labeling dispositions (2318/02 Annex III.B and later 727/2013 rules). Leave space for the Argentine registration number; do not print a draft ANMAT number you do not have.
    • Declaration of Conformity for the Class I/II route; full technical file upload for Class III/IV.

    Translations, legalizations, and government fees

    Spanish is not a “nice to have.” HELENA wants PDFs the reviewer can read. Apostille plus traductor público is the usual foreign-document path. Budget calendar time for the CFS and ISO legalizations first; they sit on other agencies’ desks, not ANMAT’s.

    Government fees (aranceles) are published in Argentine pesos by class and move with ANMAT’s fee resolutions and FX. Practitioner ranges you will see quoted in 2026 sit in the low hundreds of U.S. dollars per product for the ANMAT tariff itself — not the total market-entry cost. AAR retainers, certified translations, dossier assembly, and deficiency responses dwarf the tariff. Do not plan around a single invented “flat fee.” Verify the current ANMAT arancel before you lock a purchase order.

    After the number: five-year clock and technovigilance

    Registrations are typically valid five years. Revalidation is due in the 90 days before expiry (Disposición 2318/02 / 727/2013 practice). Miss it and you are not “a little late” — you are often back to a new inscription. Post-market, Disposición 8194/2023 (good technovigilance practices) sits on the holder. Field actions and serious incidents do not wait for the U.S. weekend.

    FAQ-style close

    Does FDA clearance register the device in Argentina? No. It supports the CFS/CFG and the technical story. ANMAT still issues its own inscription.

    Can we file without a local holder? Not if you have no Argentine legal presence. The AAR is the applicant ANMAT recognizes.

    Is this the same as an ANMAT clinical-trial submission? No. Trial authorizations (and provincial ethics layers) are a different pathway. Do not reuse a trial SOP as a registration dossier.

    How should a U.S. sponsor sequence Argentina against other LATAM filings? Lock classification, CFS freshness, and an independent holder before you promise a launch quarter. Then run translations and GEMHA/HELENA access in parallel. If you already hold FDA or CE authorization and want a structured register-and-hold model rather than a one-off distributor filing, bioaccess® publishes that offer separately on the LATAM Launch Subscription / market-access page.

  • 7 Strategies to Leverage the 510 k FDA Database for Medtech Success

    7 Strategies to Leverage the 510 k FDA Database for Medtech Success

    Introduction

    Navigating the intricate landscape of medical device regulation presents significant challenges for Medtech innovators, particularly regarding the pivotal 510(k) submission process. This comprehensive database not only serves as a gateway to market entry in the U.S. but also provides invaluable insights that can shape successful application strategies.

    However, with nearly one-third of submissions facing rejection, it becomes essential to understand how to effectively leverage the 510(k) FDA database.

    What strategies can Medtech companies employ to enhance their chances of success and streamline their path to approval?

    bioaccess®: Accelerating Clinical Research for Medtech Innovators

    bioaccess® excels in delivering tailored for . By leveraging the , the diverse patient demographics in the Balkans, and the , bioaccess® achieves ethical approvals in an impressive 4-6 weeks. This expedited process significantly accelerates , allowing Medtech companies to enter the market more swiftly and improve .

    With over 15 years of expertise in , bioaccess® stands as a vital ally for Medtech startups navigating a competitive landscape. Industry leaders underscore that rapid are critical for fostering innovation and meeting the evolving demands of healthcare.

    As trends in 2025 suggest a heightened focus on agility and efficiency in , successful partnerships in early-phase studies will be essential for Medtech companies striving to thrive in this dynamic environment.

    At the center is bioaccess®, branching into various aspects of its services and impact. Follow the connections to understand how each region and factor contributes to faster clinical trial processes.

    Understanding the 510(k) Submission Process: Key Steps and Requirements

    The application process for , detailed in the , is crucial for bringing these products to market in the U.S. and encompasses several critical steps.

    1. Confirm whether your device necessitates a submission in the .
    2. Identify a suitable predicate device that demonstrates .
    3. Compile , including device descriptions, intended use statements, and performance data.
    4. Submit the to the FDA, ensuring that you reference the and address any inquiries or requests for additional information from the FDA.

    With for initial evaluation, understanding these steps is vital for compliance and ensuring a smooth review process. Regulatory experts, including Ana Criado and Katherine Ruiz, emphasize that meticulous preparation is essential to avoid common pitfalls that can delay market entry. A can significantly expedite market entry, reducing wasted time and resources. As Alex Pavlović states, “A right-first-time 510(k) approach gets you to market faster, eliminating wasted time and effort while generating revenue more quickly.”

    According to the , the is 175 days, with a median of 85 days, underscoring the importance of and preparation. Additionally, potential costs associated with third-party testing should be considered, as they can impact the financial planning of Medtech companies navigating the .

    Each box represents a step in the submission process — follow the arrows to understand how to navigate from confirming your device's need for submission all the way to submitting your application and handling FDA inquiries.

    Identifying Predicate Devices: A Critical Component of 510(k) Submissions

    To identify an appropriate , manufacturers must conduct thorough research within the . It is crucial to search for items that possess and technological features. The must have been legally marketed in the U.S. prior to the submission of your product. This comparison is essential for demonstrating , a key requirement for obtaining clearance from the . Experts emphasize the importance of leveraging extensive compliance knowledge to navigate this process effectively. Furthermore, comprehending both local and international is vital when identifying predicate instruments.

    Follow the arrows to see each step involved in identifying predicate devices — from research to compliance knowledge, each step is crucial for successful submissions.

    Common Challenges in the 510(k) Submission Process: What to Avoid

    The presents several common challenges that can hinder approval. Key issues include:

    1. , which can lead to delays
    2. Inadequate demonstration of , essential for establishing the device’s safety and effectiveness
    3. Misidentification of , which can result in unnecessary complications
    4. Ambiguity in the , which must be clear to avoid confusion during review

    To navigate these pitfalls effectively, it is crucial to ensure that all documentation is comprehensive, precise, and well-organized. Interacting with compliance advisors can offer beneficial perspectives and assistance, aiding in clarifying intricate requirements and simplifying the . For instance, companies that have successfully overcome these challenges often emphasize the importance of and the use of detailed checklists to ensure compliance with . By adopting these strategies, can enhance their chances of a successful application in the 510 k FDA database.

    The center represents the overall topic, while each branch identifies a specific challenge. Sub-branches suggest strategies to address these challenges, making it easy to navigate potential pitfalls.

    Ensuring Regulatory Compliance: Navigating the 510(k) Landscape

    To ensure compliance with regulations during the , manufacturers must possess a thorough understanding of the , including its guidelines and requirements. Adherence to the is essential, as it mandates that all records related to the be accurate, complete, and accessible. Comprehensive and meticulously recorded testing data is critical for a successful entry.

    Regularly reviewing updates from the FDA is imperative, considering that approximately 30% of applications listed in the were placed on Refuse to Accept (RTA) hold in 2018 due to inconsistencies. Establishing a proactive approach for oversight monitoring can significantly enhance a company’s ability to navigate the complexities of the submission process and secure timely approvals.

    Furthermore, manufacturers must implement processes for identifying, documenting, and managing nonconforming products, which is a crucial aspect of compliance under . Experts underscore the necessity of understanding , where insights from seasoned regulatory consultants can offer invaluable guidance in effectively navigating these challenges.

    Each box represents a critical step in ensuring compliance. Follow the arrows to see how each step leads to the next in successfully navigating the 510(k) landscape.

    Interpreting FDA Feedback: A Guide for Medtech Innovators

    When receiving , it is essential to analyze the comments and meticulously. should be a top priority, as neglecting this can lead to delays or even . is crucial; therefore, consider to clarify any points of confusion. Additionally, document all interactions to ensure a comprehensive understanding of the feedback provided.

    Each box in the flowchart represents a key step in responding to FDA feedback. Follow the arrows to understand the order of actions that should be taken to ensure a successful response.

    Adapting to Changes in the 510(k) Program: What Medtech Innovators Need to Know

    The 510 k is undergoing continuous enhancements aimed at improving both efficiency and safety. Medtech innovators, including experts like Ana Criado, Director of Regulatory Affairs and a professor in biomedical engineering, must stay abreast of new guidelines, such as the introduction of the for applications. Grasping these changes is crucial for companies to adapt their and ensure compliance with the latest requirements.

    Regularly reviewing and participating in industry discussions can provide valuable insights into upcoming modifications, particularly for those involved in oversight of . Additionally, insights from Katherine Ruiz, a compliance specialist for in Colombia, can further deepen understanding of these evolving guidelines.

    In the center, you'll find the main topic. Each branch represents crucial areas that medtech innovators need to consider, with details expanding from each branch to provide a deeper understanding of how to adapt to these changes.

    Effective Communication with Regulatory Bodies: Best Practices for 510(k) Submissions

    To foster with , Medtech firms must prioritize transparency throughout the application process. Establishing is essential, as it cultivates a collaborative relationship with the FDA. Engaging in can significantly enhance the likelihood of ; studies indicate that products receiving such early engagement boast a 52% approval rate, compared to just 29% for those that do not. These meetings provide a crucial opportunity to clarify expectations and address potential concerns prior to formal submission, ultimately streamlining the review process.

    Furthermore, maintaining well-organized and concise documentation is paramount. The must encompass a description of the product’s attributes alongside a comprehensive list of all product components, facilitating understanding and demonstrating professionalism and a commitment to compliance. Effective documentation should also feature detailed comparisons with predicate devices and evidence of while adhering to accepted standards. from the FDA reinforce a company’s dedication to compliance with regulations, which is essential for successful filings in the . As emphasized by industry specialists such as Ana Criado and Katherine Ruiz, who possess significant expertise in regulatory matters, comprehensive and transparent documentation is fundamental to , ensuring that all essential information is readily accessible and clearly articulated.

    This flowchart illustrates critical steps in the communication process with regulatory bodies. Each box represents a step, and the arrows show how these steps connect to improve the likelihood of successful regulatory submissions.

    Leveraging Insights from the FDA 510(k) Database: Strategies for Success

    The is a crucial resource for aiming to enhance their application strategies. By meticulously analyzing previously cleared devices, companies can extract valuable insights into , such as identifying common predicate devices and mastering . This empowers innovators to , showing which data types have historically led to successful applications. Notably, around 85 percent of receive a , underscoring the importance of aligning with established benchmarks. By harnessing these insights, companies can refine their strategies, significantly boosting their chances of securing a successful . Industry leaders stress the necessity of leveraging these trends to inform strategic decisions, ensuring that submissions are compliant and competitive within the dynamic regulatory landscape.

    The central node represents the main focus on leveraging the FDA database. Each branch shows different strategies and insights that can help medtech innovators enhance their application approaches — the further you go out, the more detailed the information becomes.

    Conclusion

    Leveraging the 510(k) FDA database is imperative for Medtech innovators striving to navigate the complexities of regulatory submissions with efficiency. By comprehensively understanding the submission process, identifying predicate devices, and maintaining effective communication with regulatory bodies, companies can significantly enhance their prospects for successful product approvals. The insights garnered from the 510(k) database not only streamline applications but also cultivate a deeper understanding of market trends and compliance requirements.

    Throughout this article, key strategies have been articulated, emphasizing the critical nature of meticulous documentation, proactive engagement with the FDA, and the necessity of thorough pre-submission planning. These elements are essential in overcoming common pitfalls that can impede market entry, such as incomplete submissions and misidentified predicate devices. Moreover, remaining informed about evolving regulations and leveraging expert guidance can further strengthen a company’s position within the competitive Medtech landscape.

    As the Medtech industry continues to transform, embracing these strategies will be vital for companies aiming to excel. Innovators are encouraged to actively engage with the 510(k) FDA database, refine their submission approaches, and prioritize compliance. By doing so, they not only enhance their chances of successful applications but also contribute to advancing healthcare solutions that ultimately improve patient outcomes.

    Frequently Asked Questions

    What services does bioaccess® provide for Medtech innovators?

    bioaccess® offers rapid clinical research services tailored for Medtech innovators, leveraging regulatory efficiency in Latin America, diverse patient demographics in the Balkans, and streamlined pathways in Australia to achieve ethical approvals in 4-6 weeks.

    How does bioaccess® impact product development timelines for Medtech companies?

    By providing expedited ethical approvals, bioaccess® significantly accelerates product development timelines, allowing Medtech companies to enter the market more swiftly and improve patient outcomes.

    What experience does bioaccess® have in clinical studies?

    bioaccess® has over 15 years of expertise in early-phase clinical studies, making it a vital ally for Medtech startups in a competitive landscape.

    What is the significance of rapid clinical research services in the Medtech industry?

    Rapid clinical research services are critical for fostering innovation and meeting the evolving demands of healthcare, especially as trends in 2025 indicate a focus on agility and efficiency in clinical trials.

    What are the key steps in the 510(k) submission process for medical devices?

    The key steps include confirming if a submission is necessary, identifying a suitable predicate device, compiling comprehensive documentation, and submitting the 510(k) application to the FDA.

    Why is it important to understand the 510(k) submission process?

    Understanding the process is vital for compliance and ensuring a smooth review, as 30% of entries in 2022 were not accepted for initial evaluation. Proper preparation can avoid delays and expedite market entry.

    What is the average approval time for a 510(k) application?

    The average approval time for a 510(k) application is 175 days, with a median of 85 days.

    How can manufacturers identify appropriate predicate devices for 510(k) submissions?

    Manufacturers can identify predicate devices by conducting thorough research within the 510(k) FDA database, looking for items with comparable intended applications and technological features that have been legally marketed in the U.S. prior to submission.

    What is the importance of demonstrating substantial equivalence in 510(k) submissions?

    Demonstrating substantial equivalence is a key requirement for obtaining clearance from the 510(k) FDA database, making it essential for manufacturers to identify appropriate predicate devices effectively.

    What should Medtech companies consider regarding costs in the 510(k) submission process?

    Medtech companies should consider potential costs associated with third-party testing, as these can impact their financial planning while navigating the 510(k) submission process.

    List of Sources

    1. bioaccess®: Accelerating Clinical Research for Medtech Innovators
      • medtechsuperconnector.com (https://medtechsuperconnector.com/case_studies/william-oak-diagnostics)
      • theksquaregroup.com (https://theksquaregroup.com/all_case_studies)
    2. Understanding the 510(k) Submission Process: Key Steps and Requirements
      • greenlight.guru (https://greenlight.guru/blog/fda-510-k-submission)
      • qualio.com (https://qualio.com/blog/fda-510k-submission)
    3. Common Challenges in the 510(k) Submission Process: What to Avoid
      • solemglobal.com (https://solemglobal.com/articles/case_studies/creating-an-effective-budget-impact-model-bim-and-academy-of-managed-care-pharmacy-amcp-dossier)
    4. Ensuring Regulatory Compliance: Navigating the 510(k) Landscape
      • hmpi.org (https://hmpi.org/author/kirsten)
      • kolabtree.com (https://kolabtree.com/blog/13-mistakes-to-avoid-in-a-510k-submission-for-quick-fda-clearance)
      • 10 Key Insights on Code of Federal Regulations Title 21 Part 820 | bioaccess® (https://bioaccessla.com/blog/10-key-insights-on-code-of-federal-regulations-title-21-part-820)
      • The Top 5 Challenges in Medical Device Regulatory Compliance and How to Overcome Them – Nerac (https://nerac.com/the-top-5-challenges-in-medical-device-regulatory-compliance-and-how-to-overcome-them)
      • search.proquest.com (https://search.proquest.com/openview/1bd0dea35246219efecc64eb940c91b7/1?pq-origsite=gscholar&cbl=18750)
    5. Effective Communication with Regulatory Bodies: Best Practices for 510(k) Submissions
      • qualysec.com (https://qualysec.com/fda-510k-submission)
      • thefdagroup.com (https://thefdagroup.com/blog/510k-explained)
      • complianceonline.com (https://complianceonline.com/resources/5-best-practices-medical-device-companies-must-follow-for-successful-510k-submissions.html)
      • fda.gov (https://fda.gov/industry/prescription-drug-user-fee-amendments/independent-evaluation-fdas-first-cycle-review-performance-retrospective-analysis-final-report-text)
    6. Leveraging Insights from the FDA 510(k) Database: Strategies for Success
      • qualysec.com (https://qualysec.com/fda-510k-compliance-requirements-guidance-for-approval)
      • 5 Medical Device Regulatory Approval Statistics You Need to Know – Arrotek | Medical Device Innovation (https://arrotek.com/5-medical-device-regulatory-approval-statistics-you-need-to-know)
      • bioaccessla.com (https://bioaccessla.com/blog/510-k-clearance-vs-approval-a-comparative-analysis-of-fda-pathways)
      • elexes.com (https://elexes.com/510k-submission-updates-2025)
      • haynesboone.com (https://haynesboone.com/news/alerts/the-fda-provides-clarity-on-transferring-a-510k-clearance)